Table 1.

Genetic or pharmacologic downregulation of PKA in Pkd1^RC/RC mice

Group (sex)	Body Weight (g)	Kidney Weight (g)	Kidney/Body Weight × 100	Cyst Index (%)	Urine Volume (ml/day)	Kidney cAMP (pmol/mg protein)	Plasma Creatinine (mg/dl)	Plasma Urea (mg/dl)	PKA Activity (pmlol ATP/min per mg protein)
									Basal	Total
Conditional expression of the dominant negative RIαB allele in Pkd1RC/RC mice
Control (female, n=28)	21.9±1.3	0.47±0.11	2.16±0.48	14.1±5.4	1.31±0.83	12.13±5.8	0.31±0.10	57.2±12.9	329±75	2366±497
RIαB-ON (female, n=9)	21.9±1.7	0.35±0.04	1.62±0.16	8.99±3.26	2.09±1.04	4.98±1.39	0.17±0.08	39.0±12.5	318±68	1570±306
P valuea	0.99	<0.001	<0.001	0.002	0.07	<0.001	<0.001	0.002	0.67	<0.001
Control (male, n=43)	29.1±2.35	0.58±0.14	1,99±0.43	13.5±7.4	2.37±0.91	9.74±3.4	0.32±0.11	56.1±13.3	543±171	3196±692
RIαB-ON (male, n=15)	29.7±2.49	0.49±0.14	1.64±0.49	9.41±3.77	2.73±0.85	6.47±2.82	0.29±0.06	50.6±9.12	492±190	2061±537
P valuea	0.41	0.037	0.023	0.009	0.18	0.001	0.14	0.09	0.37	<0.001
Group effect P valueb	0.54	<0.001	<0.001	0.003	0.010	<0.001	<0.001	<0.001	0.38	<0.001
Sex effect, P valueb	<0.001	<0.001	0.48	0.94	<0.001	0.65	0.008	0.09	<0.001	<0.001
Treatment of Pkd1RC/RC mice with the PKA inhibitor BLU2864
Control (female, n=10)	23.3±2.2	0.65±0.17	2.77±0.53	26.3±5.7	1.45±0.08	28.9±7.2	0.39±0.04	54.6±9.6	466±91	2585±654
BLU2864 (female, n=9)	23.5±1.1	0.54±0.07	2.28±0.33	18.9±5.0	1.72±0.36	27.6±7.7	0.36±0.06	60.2±14.6	153±31	436±130
P valuea	0.80	0.069	0.029	0.007	0.057	0.71	0.30	0.34	<0.001	<0.001
Control (male, n=9)	27.9±1.8	0.98±0.12	3.53±0.39	31.2±4.6	1.39±0.09	34.4±6.4	0.39±0.04	58.3±5.4	442±97	2167±483
BLU2864 (male, n=9)	27.1±1.8	0.80±0.16	2.93±0.49	25.9±5.9	1.67±0.14	31.1±5.7	0.40±0.05	60.6±5.5	128±34	322±128
P valuea	0.38	0.012	0.011	0.049	<0.001	0.26	0.76	0.40	<0.001	<0.001
Drug effect P valueb	0.63	0.003	<0.001	<0.001	<0.001	0.31	0.53	0.22	<0.001	<0.001
Sex effect, P valueb	<0.001	<0.001	<0.001	0.002	0.41	0.053	0.21	0.52	0.31	0.07

Values are mean±SD.

^at test.

^bTwo-way ANOVA.